{'fraction_non_alphanumeric': 0.029223744292237442, 'fraction_numerical': 0.042922374429223746, 'mean_word_length': 5.335260115606936, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
LONG‐TERM TREATMENT WITH A NEW NON‐ERGOT LONG‐ACTING DOPAMINE AGONIST, CV 205‐502, IN WOMEN WITH HYPERPROLACTINAEMIA

Twenty‐four hyperprolactinaemic women were treated for 6 months with the new, non‐ergot, long‐acting dopamine agonist, CV 205‐502. The treatment resulted in normalization of PRL secretion in 17 of the 24 women at once‐daily doses of 005 to 0‐15 mg of the drug. Sixteen of these women as well as 4 of those who remained hyperprolactinaemic had regular menstrual bleeding. Five of the patients had previously discontinued bromocriptine therapy because of adverse effects but had no problems tolerating CV 205‐502. Of three bromocriptine‐resistant women, two responded partially while one also remained unresponsive to CV 205‐502 treatment. Mild to moderate galactorrhoea was recorded at baseline in 19 of the 24 women. After 6 months’treatment mild galactorrhoea was still present in six patients, four of whom had attained normal PRL levels. Side‐effects were mild and transient. CV 205‐502 seems to be a valuable compound in the management of patients with hyperprolactinaemia.